Diane Longo, Senior Scientist, presents, "Representation of Efavirenz-mediated Drug-Induced Liver Injury (DILI) Using Quantitative Systems Toxicology (QST)"
How to Partner With Us
Scientific guidance based on subject knowledge
Application of the DILIsym® QST drug-induced liver injury model to evaluate the carcinogenic hazard potential of acetaminophen
Brett Howell, Divisional President, presents an overview of DILIsym® software, Acetaminophen risk assessment, and observations
Population Pharmacokinetic Evaluation and Missed-Dose Simulations for Eslicarbazepine Acetate Monotherapy in Patients with Partial-Onset Seizures
Luann Phillips, Distinguished Scientist of Pharmacometrics, discusses the issues, repercussions, and methods in her presentation titled, "Population Pharmacokinetic Evaluation and
Missed-Dose Simulations for Eslicarbazepine Acetate Monotherapy in Patients With Partial-Onset Seizures"
Exposure Response Modeling from the CLARITY Trail of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder
In the CLARITY trial, a placebo-controlled, phase 2 trial of patients with major depressive disorder and inadequate reposnse to selective serotonin reuptake...
Closing Remarks
Evolving relationship between M&S and pharma R&D
Prediction of Plasma Concentrations Using In Silico Modeling and Simulation Approach: Case of Acebutolol
The aim of this study was to predict the plasma concentrations of acebutolol tablets with different dissolution profiles using computer modelling and evaluating whether they are bioequivalent using simulated population studies.
Introduction Pre-Clinical M&S
Preclinical M&S Track
Introduction to ADMET Predictor®
ADMET Predictor Overview
Predicting optimal scheduling of drug combinations in lung cancer xenografts using a population PK/PD model
Bevacizumab-pemetrexed/cisplatin is a first-line therapeutic for advanced nonsquamous non-small cell lung cancer.
Introduction to FIH/Phase 1 Track
Application of Modeling & Simulation in Phase 1
Confidence in FIH PBPK models
PBPK modeling, with verification of predictive performance first performed in preclinical species, is superior to empirical methods for...
How We Build & Validate Industrial Strength Models
A strong, reliable tool tailored to the particular demands of the relevant endpoint that will get you...
Using a population mechanistic TMDD model calibrated on preclinical monkey data to simulate first-in-human
Which dose to choose to elicit the desired effect (efficacy), without causing harm (safety)?
Using a population PK/PD model developed on phase I to select the dose for Phase II: an example with an IgG1 mAb
Dosing of 30 mg/kg Q4W could guarantee >90% inhibition of membrane-bound receptor for 9 in 10 individuals
The Role of Modeling & Simulation (M&S) in Regulatory Decision Making
M&S Roles in Determining Clinical Doses
HTPK: A bridge to Early Development
Develop a simplified early PK assessment tool for non DMPK experts
Model-Based Meta-Analysis of Anti-tuberculosis Regimen Efficacy in Relapsing Mouse Model Studies
Although temporarily eclipsed by the COVID-19 pandemic, tuberculosis (TB) remains the leading infectious disease-related cause of death in the world
Pharmacometrics in Phase 1: First in Human and Dose Selection for Phase 2
Drug development and Phase 1 studies
GastroPlus® DDI Standards Update Project
Creation of a GastroPlus® project starts with structure import using ADMET Predictor Module for both substrates and perpetrators